

## Special Issue

# Advanced Research of Cartilage Repair and Regeneration

### Message from the Guest Editor

Arthritis is the most common cause of disability, the most common form of which is osteoarthritis (OA). Early OA is treated with joint-preserving interventions such as lifestyle modification, pharmaceuticals, and surgery. The most commonly used surgical modalities for the treatment of localized cartilage lesions in early OA are microfracture, mosaicplasty (osteochondral autograft), and autologous chondrocyte implantation. These therapies may restore function and relieve pain for a short period, but they are not able to arrest or delay disease progression. End-stage OA is treated with joint replacement; however, the functional outcomes can be poor and the lifespan of prostheses is limited. New strategies based on mesenchymal stem cells are being actively tested in humans and animals; however, few have been successfully translated into clinical practice. This Special Issue on Advanced Research of Cartilage Repair and Regeneration invites original and review articles focusing on stem cells, scaffold, and chondrogenic factors as well as their combinations for articular cartilage regeneration and repair. In vivo animal studies with long-term follow-up are particularly welcome.

### Guest Editor

Prof. Dr. Zongbing You

Department of Structural & Cellular Biology, Tulane University, New Orleans, LA 70112, USA

### Deadline for manuscript submissions

closed (31 May 2023)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/152558](https://mdpi.com/si/152558)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).